Sonic Healthcare (ASX:SHL) reported results in line with its guidance, with statutory net profit for the year to 30 June 2019 up 16 per cent to $550 million.
Strategically SHL says its business has taken major steps forward diving into the anatomical markets in the USA and Germany, opening up new pathways for future growth. SHL has 1,000 pathologists, 200 radiologists, 2,000-plus partner GPs and thousands of qualified scientists and technical staff, all of which underpin its healthcare offering.
Revenue growth saw a 12 per cent lift to $6.2 billion Underlying EBITDA grew 10 per cent to $1.1 billion.
As for EPS, that grew 9 per cent, but and impacted by the Aurora acquisition-related capital raising and a $20 million one-off tax benefit in the prior year. Total Dividends for 4 per cent to $0.84 in FY19.
Sonic Healthcare (ASX:SHL)
shares are up 12.4 per cent year-on-year. Sonic Healthcare (ASX:SHL)
are trading 3.1 per cent higher at the minute, at $28.60.